Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 908491
                    [Title] => Tolvaptan effective for hyponatremia for patients with heart failure — trials
                    [Summary] => 
Tolvaptan, a new vasopressin V2-receptor antagonist and the first and only oral drug in its class, has been shown in clinical trials to be an effective treatment for hypervolemic and euvolemic hyponatremia, especially for patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

                    [DatePublished] => 2013-02-14 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

TOLVAPTAN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 908491
                    [Title] => Tolvaptan effective for hyponatremia for patients with heart failure — trials
                    [Summary] => 
Tolvaptan, a new vasopressin V2-receptor antagonist and the first and only oral drug in its class, has been shown in clinical trials to be an effective treatment for hypervolemic and euvolemic hyponatremia, especially for patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

                    [DatePublished] => 2013-02-14 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Tolvaptan effective for hyponatremia for patients with heart failure — trials

February 14, 2013 - 12:00am

Tolvaptan, a new vasopressin V2-receptor antagonist and the first and only oral drug in its class, has been shown in clinical trials to be an effective treatment for hypervolemic and euvolemic hyponatremia, especially...

Science and Environment